Safety and preliminary efficacy from the phase 1 portion of MasterKey-01: A First-in-human dose-escalation study to determine the recommended phase 2 dose (RP2D), pharmacokinetics (PK) and preliminary antitumor activity of BDTX-189, an inhibitor of allosteric ErbB mutations, in patients (pts) with advanced solid malignancies Meeting Abstract
| Authors: | Schram, A. M.; Ahnert, J. R.; Patel, M. R.; Jauhari, S.; Sachdev, J. C.; Zhu, V. W.; LoRusso, P.; Nguyen, D.; Le, X.; O'Connor, M.; Waters, N.; Cook, C.; Witt, K.; Humphrey, R. W.; Janne, P. A.; Hamilton, E. P. |
| Abstract Title: | Safety and preliminary efficacy from the phase 1 portion of MasterKey-01: A First-in-human dose-escalation study to determine the recommended phase 2 dose (RP2D), pharmacokinetics (PK) and preliminary antitumor activity of BDTX-189, an inhibitor of allosteric ErbB mutations, in patients (pts) with advanced solid malignancies |
| Meeting Title: | 2021 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 39 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2021 Jun 4-8 |
| Meeting Location: | Virtual |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2021-05-20 |
| Language: | English |
| ACCESSION: | WOS:000708120601260 |
| DOI: | 10.1200/JCO.2021.39.15_suppl.3086 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 3086 -- Source: Wos |
